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Free radicals may be involved in the aetiology of cancer
and cardiovascular diseases. In epidemiological studies
poor plasma levels of all essential antioxidants are
associated with increased relative risks; in particular, low
levels of carotene and vitamin E with the risk of cancer
and ischemic heart disease, respectively. The studies
suggest that for optimal synergistic protection the plasma
antioxidant levels should simultaneously exceed the
threshold values of 28-30 umol/l lipid-standardized vitamin
E, 40-50 |imol/l vitamin C, 0.4-0.5 (imol/l carotene and
2.2-2.8 umol/l lipid-standardized vitamin A. However the
preventive efficacy of an optional antioxidant status is still
to be proven in randomized intervention trials. Although
these antioxidant micronutrients may be the primary
protective components of vegetable-rich 'preventive' diets,
the potentials of other plant components await exploration,
eg carotenoids other than {}-carotene, bioflavonoids and
oxygen-sensitive B-vitamins.
Aggressive oxygen species (superoxide anion radical, hydroxyl radi-
cal, hydrogen peroxide and singlet oxygen, carbon-centered and thiyl
radicals can damage all biochemical components, ie DNA/RNA, pro-
teins, carbohydrates, unsaturated lipids and micronutrients such as
carotenoids, vitamins A, Bg, B1 2 and folate. Lipid peroxidation can
proceed as a chain reaction producing hydroperoxides and aldehydes
which can damage at distance.1-3 Free radicals have been implicated
in the aetiology of many diseases.1"3 Unfortunately the extremely short
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half-life of most aggressive radical species prevents direct investigation.
But indirect information is available from measuring antioxidants which
are crucial in the body's multilevel defence against radicals. Lines of de-
fence include enzymes (eg superoxide dismutase, catalase, glutathione
peroxidase), non-essential endogenous antioxidants (glutathione, pro-
teins, uric acid, ubiquinol-10 etc) and essential radical scavengers, ie
vitamins C (ascorbic acid) and E (a-tocopherol), carotenoids (eg p-
carotene, a potential vitamin A precursor with singlet oxygen-quench-
ing effects, and non-vitamin A precursors, e.g. lycopene) and finally vi-
tamin A (retinol, potentially a thiyl radical scavenger).1-3 The first line
of essential antioxidants is formed by vitamin C, the principal radical
scavenger of the aqueous phase,4"5 which is also primarily exhausted
by coronary bypass surgery (a special reperfusion injury of heart/lung).6
Vitamin E represents the principal chain-breaking antioxidant in the li-
posoluble phase.3 This review summarizes inverse associations between
essential antioxidants in plasma and cancer (International Classification
of Diseases: ICD 140-239), cardiovascular diseases (CVD) such as
ischemic heart disease (IHD; ICD 410-^-14)7-12 and stroke (cerebrovas-
cular disease; ICD 430-438)12 which suggest a pathogenetic involve-
ment of free radicals. If free radicals are aetiologically involved in the
major causes of death, optimization of antioxidant status should offer
preventive prospects for 'optimum health' as defined by WHO. The
status of vitamin antioxidants (in contrast to that of other antioxidative
defence lines) can easily, and without risking side effects, be modified
by dietary measures.
VEGETABLE-RICH DIETS
Many nutritional surveys demonstrate a higher life expectancy and
lower risk of cancer and IHD in subjects preferring special diets such as
a vegetable-rich (not necessarily truly vegetarian) type and the Mediter-
ranean diet. The latest dietary guidelines recommend a lowering of total
dietary fat (primarily the mammalian fat, but with a relative increase of
monoene-rich vegetable oils) together with an increased consumption
of green-yellow vegetables and fruits. An optimized diet might theo-
retically reduce the incidence of cancer by 30-60%.13 Vegetable/fruit-
enriched diets may increase plasma levels of vitamin C and carotene,
and vegetarians have also a higher ratio of vitamin E/polyunsaturated
fatty acids (PUFAs, the major substrate of lipid peroxidation).14- 15
Although the principal antioxidant vitamins, vitamins C and E, to-
gether with P-carotene and vitamin A may be primarily related to the
reduction of radical-related pathogenicity, supplementary contributions
could come from further plant components, eg carotenoids other than
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p-carotene such as lycopene, bulky strong antioxidants such as com-
mon phenols and mostly poorly absorbable bioflavonoids (potentially
protecting principal antioxidants such as vitamin C), oxygen radical-
sensitive B-vitamins such as folate and vitamin Bg (probably requiring
protection by a fair vitamin C status in vivo).16- 17
CALCULATED DIETARY INTAKE OF ESSENTIAL
ANTIOXIDANTS
Dietary surveys based on Food Composition Tables consistently reveal
inverse correlations between essential nutrient antioxidants and the risk
of cancer1^-20 and IHD.7-10 Preliminary data of the US Nurses Study21
suggest a reduced risk of IHD at the highest intake of either vitamin E
or A or carotene. The First National Health and Nutrition Examination
Survey (NHANES I) reveals that an increased vitamin C intake gives
substantial risk reductions for all causes of death, all cancers and all
CVD.22 According to a preliminary subset analysis of the US Physici-
ans Study supplementation of P-carotene (alternately with aspirin) can
also reduce the IHD risk.23
OBSERVATIONAL DATA ON PLASMA LEVELS OF
ANTIOXIDANT NUTRIENTS
Several complementary types of epidemiological studies in westernized
countries have revealed that increased risks for cancer, IHD and stroke
are associated with a poor plasma status of essential antioxidants such
as vitamins C and E as well as carotene and vitamin A. Clearly plasma
levels are more conclusive indicators of the antioxidant status than the
calculated dietary intake since the actual status in vivo is the outcome of
the bioavailability of antioxidants (depending on dietary supply, intesti-
nal absorption, hepatic secretion and metabolic regulations) and of the
individual requirement which can be increased by peroxidation-prone
nutrients such as PUFAs, by 'oxidative stress', by the environment
(including smoking) or by life-style factors, eg exhaustive exercise and
possibly catecholamine-related stress.
PREDICTION OF CANCER BY LOW PLASMA ANTIOXIDANT
NUTRIENTS
Case-control studies
Several studies found lower plasma carotene and vitamin E in patients
with existing cancers, eg of the lung,24-2^ presumably at least in part
because of a lower dietary intake.24- 2^ But retrospective case-control
studies of malignant tumors are of limited value since they cannot
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distinguish between cause and result of the disease which is mostly
diagnosed only decades after its initiation.
Prospective studies
The longitudinal follow-up of initially apparently healthy subjects up
to 12 years in about 10 study populations revealed that the subsequent
cancer mortality was, when compared to surviving controls, inversely
related to initial levels of P-carotene (or a -plus B-carotene), and in part
also to levels of vitamins E, C and A (Table I).27-50 Whereas prospec-
tive cohort studies have mostly a 'blood-bank' design (with a great loss
of carotenoids and a marked vitamin E decay in frozen serum stored
for years) this handicap was avoided by the Basle Prospective Study,
and the latter was also unique in the simultaneous assay of plasma
vitamin C. Sequential evaluations of the Basle Study27- 30-32, 35, 37
consistently revealed a very strong predictive power of a poor carotene
status for most cancers (Figs. 1 & 2) thus confirming other studies
with the storage handicap (Table 1) and further favouring the idea
that B-carotene is a substantial component of preventive vegetable-rich
diets.13 In addition, the Basle Study established a significantly increased
relative risk of gastrointestinal cancers at low plasma concentrations
of vitamin C3°-32> 37 and at low levels of lipid-standardized vitamin
A37 (Figs. 1 & 2). This substantiates nutritional data on inverse cor-
relations between dietary vitamin A18 or vitamin C22. 51 and risk of
subsequent cancers. It is unknown why the cancer risk is clearly pre-
dicted by lipid-standardized plasma vitamin A but rather not by abso-
lute plasma vitamin A which revealed no consistent correlations or, at
best, trends.I6- 18. 28- 33> 36> 43- 47 Finally, the Basle Study may indi-
rectly support results from other study cohorts with a presumably poor
vitamin E status which revealed an increased cancer risk at the lowest
percentiles of vitamin E (Table 1). Thus, the unusually and uniformly
high vitamin E levels in Basle lacked (at most follow-ups) a signif-
icant correlation to subsequent cancer (Figs. 1 & 2), most probably
since all vitamin E values of the Basle population were above the risk
threshold35. 37 similar to other populations with high vitamin E status,
e.g. in Hawaii.28 Clearly, an increased risk of a poor level of any anti-
oxidant can only be revealed if the latter occurs in a statistically suf-
ficient percentage of study subjects. This happened in the Basle Study
for the antioxidants mentioned above but not for vitamin E.35 Since
the Basle population (men of 30-65 years of age) did not show any
age-dependent variation of all the plasma vitamins measured (Gey KF,
Stahelin HB, LUdin E, unpublished data, 1990), the differences of the
antioxidant status between deceased cases and surviving controls may
have been rather permanent ones during all stages of carcinogenesis.
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Table 1 Prospective studies on subsequent cancer mortality: a poor plasma antioxidant
status at baseline is associated with a significantly increased relative risk
Antioxidant
Carotene
Vitamin A
Vitamin C
Vitamin E
Cancer (in 5-12 years)
Lung
Gastrointestinal
Skin melanoma
All (in males)
Lung
Stomach
Prostate
All (in males)
Gastrointestinal
All (in males)
Lung
Gastrointestinal
Colorectal
Pancreas
Skin melanoma
Urinary organs
All (in males)
Breast
Female reproductive
All (in females)
Reference
27-39
27, 28, 37
39
30-37
30-32, 37, 40
30-32, 37, 40, 41
42
37, 39
30-32, 37
30-32, 37
29-32, 38, 39, 43
39, 40, 44-46
46
40
39
44
39, 43-45, 47
48,49
49
49
Taking together all prospective studies on subsequent cancers the
correlation is strongest for carotene but there are marked differences
between cancer sites.37. 50 For the relative cancer risk of the Basle
population (Fig. 2) the rank order of correlations was:
• bronchus cancer: carotene (p-, possibly also a-carotene)
>lipid-standardized vitamin A (and vitamin E in areas with
poor vitamin E status)
• gastrointestinal cancer: vitamin C = carotene >vitamin A (=
vitamin E in areas with poor vitamin E status)
• all cancers: carotene = vitamin A >vitamin C.
Furthermore, the combination of low levels of several antioxidants,
eg of both carotene and vitamin A, increased the risk additively.32. 37
In conclusion, preventive attempts should simultaneously optimize the
status of all essential antioxidants.
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Fig. 1 Mean base-line values of plasma carotene, vitamin A (retinol; lipid-standardized)
and vitamin C in cases of subsequent cancer in % of means of survivors: 12-year
follow-up of the Prospective Basel Study.37 The absolute plasma values of survivors (S)
are indicated at the bottom. The mean values for lipid-standardized vitamin E were in all
subsequent cancer cases almost identical to that of survivors, ie unusually high (mean of
survivors 34.6 jlM) and thus presumably far above any critical threshold.37
PREDICTION OF CARDIOVASCULAR DISEASE BY LOW
PLASMA ANTIOXTDANT NUTRIENTS
Consistent evidence for associations of a poor plasma status of essential
antioxidants and an increased risk of IHD has emerged from 3 comple-
mentary types of studies:
Cross-cultural epidemiology
This can reveal differences in risk factors that may be important for
early pathogenic stages, ie initiation and/or promotion of atherogenesis
(provided that younger age strata are included). Data of several coun-
tries suggest that in given study populations the antioxidant status is
fairly constant in men aged 20-65 years.10 The Vitamin Substudy of
the WHO/MONICA Project (a standardized and by far the largest trial
for Monitoring trends and determinants of Cardiovascular disease) com-
pared in randomly-selected representatives of 16 European study pop-
ulations the plasma antioxidant status with the concurrent age-specific
IHD mortality. The latter varied up to 6-fold (as in the whole world)
and antioxidant levels up to about 2-fold. In the majority (ie in 12
study populations) the classical risk factors of plasma cholesterol, blood
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Fig. 2 Relative risk of low plasma levels of essential antioxidants (at base-line) for
subsequent cancer death (first 2 years excluded) after adjustment for age, smoking and
lipids, with 95%-confidence intervals: 12-year follow-up of the Prospective Basel Study.37
Horizontal scale and numbers at the right end of the bars of 95%-confidence: Relative
risk of quartile 1 (threshold levels in the larger box at the right edge) in comparison to
quantiles 2 to 5 (with higher antioxidant levels) in the Cox proportional hazard regression
model.
pressure and smoking did not differ significantly and could thus not
sufficiently explain the up to 6-fold differences in IHD mortality.7- 8> n
The differences could, however, be predicted by a hitherto unique de-
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gree when the plasma status of essential antioxidants was simulta-
neously considered. Most impressive and consistent in all sequential
evaluations7-11' 31- 52-54 was the strong inverse correlation of vitamin
E (r2>0.6; P<0.0003) which occurred for both absolute vitamin E in
populations with comparable plasma lipoproteins and lipid-standardized
vitamin E in all study populations (Fig. 3). In univariate analysis vita-
min E was clearly a stronger predictor of IHD mortality than the classi-
cal risk factors total plasma cholesterol (r2=0.29; P=0.03) and diastolic
blood pressure (r2=0.25; 0.25; P=0.05), even after their combination in
multiple regression analysis (r2=0.44; P^O.02).54 There was practically
no overlap of the distribution pattern of vitamin E when study popula-
tions with high and low risk of IHD were compared (Fig. 4). Essential
antioxidants other than vitamin E made relatively smaller contributions
(r2<0.4-0.5) the rank order of which varied in the sequential evalu-
ations according to the accidental composition of the available study
populations.7-11- 31- 53-54 When a special, presumably in part genetic,
'Finland factor' is tentatively considered,11 vitamin C comes close to vi-
tamin E (Fig. 3). The stepwise regression analysis of the latest report,11
further complemented by data from additional study populations (KF
Gey et al., unpublished evaluations) suggests the following tentative
rank order for IHD: vitamin E »cholesterol and/or a 'genetic Finland
factor' >vitamin C >carotene = diastolic blood pressure >vitamin A.
'Finland factor' is suggested by the fact that Finnish study populations
behave as outlyers in almost all variables and are significantly different
from total cholesterol.11 This rank order of antioxidants, is, however,
limited by their known interdependence: although plasma antioxidants
can vary independently from each other in healthy individuals their
medians in populations tend to correlate (TP= 0.4-0.5), and this happens
presumably also in IHD. Nevertheless, the combination of the above
mentioned variables (emerged from stepwise regression analysis but
without vitamin A) can predict the existing IHD mortality to 90% (Fig.
5). Thus this combination of risk factors describes cross-cultural IHD
in Europe to a degree that has never been achieved before.
Case-control study in early undiagnosed angina pectoris
Common case-control studies on patients with long-standing coronary
obstruction or even acute infarction (with hormonal and metabolic con-
sequences) cannot differentiate between cause and result of the disease
(and/or previous therapy possibly affecting the antioxidant status.)10
Such weaknesses are avoidable by studying subjects whose symptoms
had previously been disregarded and whose moderate IHD had not been
diagnosed and thus not yet resulted in life style changes and/or treat-
ment. In the Edinburgh Case-Control Study on Previously Undiagnosed
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Fig. 3 Inverse correlation between age (40-59 years)-specific IHD mortality and the
medians of (logarithms of lipid-standardized) plasma vitamin E (above) and plasma
vitamin C (below): cross-cultural comparisons of male European study populations in
the Vitamin Substudy of the WHO/MONICA Project.9. "
Solid regression lines: all study populations (n=16). Dotted regression lines: correlations
of non-Finnish populations (n-=13), ie after tentative exclusion of the Finnish study
sites (dotted circles) which might have another special risk factor of IHD, the 'Finland
factor'.11
Angina Pectons55 middle-aged men from a population with plasma
antioxidant levels between sufficient/fair to poor (due to rare consump-
tion of fresh fruits and vegetables56) and a very high IHD morbidity
were screened for cases with previously undiagnosed angina pectoris
and compared with apparently healthy matched controls. Low plasma
levels (quintile 1) of vitamin E, of vitamin C and of carotene were
associated with an up to 2.6-fold higher risk of this early stage of IHD
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Fig. 4 Different distribution of lipid-standardized plasma vitamin E values in populations
with high IHD risk (Scotland - Glasgow, Edinburgh; Finland - South West and North
Karelia) and low IHD risk (Spain - Catalonia, France - Toulouse): Cross-cultural
comparisons of the Vitamin Substudy MONICA Project. The altitude of the columns
represents the % of subjects within any study population (Ordinate) with different levels
of plasma levels of lipid-standardized vitamin E (Abscissa).
as compared to high antioxidant levels (Fig. 6). Whereas the increased
risk of low vitamin C and carotene were confounded by (and most likely
mainly due to) cigarette smoking, the statistically-significant linear risk
attributable to low vitamin E was independent of classical risk factors.55
If in these Scotsmen the IHD risk of smoking is mainly mediated by
poor levels of vitamin C and carotene56 the rank order of essential
antioxidants should be similar to that in the cross-cultural MONICA
Vitamin Substudy, ie vitamin E >vitamin C = carotene >vitamin A.
Prospective data
In the 12-year follow-up of initially healthy men in the above mentioned
Basle Prospective Study the lowest quartile of lipid-standardized plasma
carotene or of vitamin C showed (after adjustment for age, cholesterol
and smoking) a statistically-significant association with an increased
IHD mortality (relative risk of low carotene 1.53, of low vitamin C 1.25,
and the combination of both 1.96; P=0.02).12 Interestingly, death by
stroke behaved correspondingly (relative risk of low carotene 2.07, low
vitamin C 1.28, of low levels of both 4.17; /><0.01 for overmultiplica-
500
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Fig. 5 Correlation between actual age-specific MD mortality in middle-aged males of
16 European study populations of the Vitamin Substudy of the MONICA/WHO Project
(Abscissa) and the IHD mortality predicted by the combination of lipid-standardized
vitamins E, total cholesterol, carotene, vitamin C and diastolic blood pressure in multiple
regression analysis (Ordinate). Recalculation of basic data from a previous publication.11
Upper graph: the combination of the variables mentioned above predicts 81 % of the actual
IHD mortality. Lower graph: additional inclusion of 'Finland factor' into the model of
multiple regression analysis increases the predictive power of the model (P=0.057) to
90%.
tive interaction).12 'Optimal' vitamin A levels may reduce mortality and
improve neurological recovery after stroke.57 At vitamin E levels above
30 (j.mol/1 no correlation has been found to death from CVD in the Basle
Prospective Study,11- 12 from IHD in a prospective Dutch study58 and
for survival after stroke57 as may be expected from (as discussed above)
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Fig. 6 Increased risk of previously undiagnosed angina pectoris in Edinburgh, Scotland,
at suboptimal plasma levels of essential antioxidants levels. The odds ratio (ordinate)
was calculated in relation to the vitamin levels in the healthy control population. Upper
graph: no adjustment for concurrent risk factors of EHD. Lower graph: adjustment by
logistic regression for age, blood pressure, total plasma cholesterol and HDL cholesterol,
triglycerides, body weight, season and smoking (the latter as major confounder being
primarily responsible for the drop of carotene- and vitamin C-related risk by adjustment).
Obviously a clear linear trend existed without adjustment for vitamins E, C and carotene
but after the adjustment the linear trend remained statistically significant (P=0.02) only
for vitamin E. 'Range' indicates plasma levels below the first and above the fifth quintile
and their quotient Q.
uniformly high vitamin E levels in both study populations (mean 35
(j.mol/1 being markedly above any critical threshold). In a prospective
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Finnish study59 the individual risk of IHD was not correlated to plasma
vitamin E either but presumably the inter-individual variation of the
notoriously poor vitamin E status in Finland8"11< 14 was too small or
within a low range of similarly increased IHD risk.
Taking the available (still incomplete) prospective findings together,
they may concur with the working hypothesis of CVD-protective po-
tentials of a high status of antioxidant vitamins. Broader prospective
data may be expected from the Prime Study which currently compares
middle-aged men in Northern Ireland (with poor antioxidant status but
high IHD risk) and France (with high antioxidant status but low IHD
risk).
INTERVENTION TRIALS
Epidemiological observations, even if complementary and consistent,
cannot reveal any causal relationship. The latter remains to be proven by
properly designed population-based intervention trials which encounter,
however, many problems, eg apparently healthy subjects at high risk
(in primary prevention studies) may poorly comply in contrast to ei-
ther health-oriented subjects at low risk or elderly patients (secondary
prevention) whose disease might be too advanced and/or too heavily
superimposed by age-related processes to be modified.
At present at least 20, mostly primary intervention trials in ran-
domized subjects with high cancer risk (eg in smokers), are sponsored
only by the National Cancer Institute, NTH, Bethesda, Maryland, testing
cancer-preventive potentials of P-carotene and/or of vitamins A, C and
E.60 Only one trial, testing secondary prevention of non-melanoma skin
cancer by P-carotene supplements (after surgical removal of the pri-
mary tumour) has been terminated: doubling of the initially rather high
(presumably 'safe') P-carotene status for 6 years lacked any beneficial
effect.61 This could be related to various design problems:
• no protective benefit when the plasma concentration already
initially exceeds the risk threshold level? Likely, by definition
of threshold (meaning minimal risk),
• testing a single component instead of an improved overall anti-
oxidant status?
Single components deserve great scientific interest but the chance of
prevention may be greater for the combination of several synergistic
antioxidants.10' 17- 18- 62-61 The first step towards IHD prevention may
be the combination of vitamins E, C and P-carotene68—logically aiming
at multirisk factor intervention in the multifactorial multi-stage IHD.
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• supplementation period (of a few years) too short or (for sec-
ondary prevention) too late at fully developed disease (as es-
tablished cancer)?
This crucial question could be answered by successful primary pre-
vention trials. Ideally any preventive measure should begin before ini-
tiation and promotion of cancerogenesis and of arteriosclerotic plaques,
respectively, ie in childhood to early adulthood but this is unrealistic.
Primary intervention trials are feasible only for about 6-8 years in
middle-aged subjects shortly before the number of diagnosable cases
will substantially increase, ie when 'sleeping' cancers start to progress
(by infiltration or metastases) or/and when previously uncomplicated,
asymptomatic arterial plaques are aggravated by age-related unspecific
arterial thickening and sclerosis and thus progress faster into compli-
cated 'abscess'-like lesions prone to fissures or eruption (causing coro-
nary thrombosis and/or extreme vasospasms and ventricular fibrilla-
tion).
Results from several other cancer prevention trials can be expected
within a few years. A fairly big cancer intervention study testing P-
carotene and/or vitamin E in Finnish smokers may be evaluated about
1994.
Large-scale IHD-related interventions are also certainly warranted.68
For primary prevention most conclusive results may be expected from
an ascertained rise of plasma antioxidants in randomized subjects at
high IHD risk at comparable age but poor antioxidant status. Secondary
prevention in IHD patients may meet many more problems, eg risk of
being too late (no experimental evidence has suggested regression of
advanced arterial lesions by antioxidant vitamins), great inhomogeneity
of complicated arterial lesions and their clinical symptoms, difficul-
ties to interpret antioxidative interactions of concurrent drug therapy.10
The high cost of intervention trials makes money-saving compromises
and/or combinations tempting but after a badly-designed study with
negative outcome there is little chance for another trial even if the latter
is perfectly designed.
THRESHOLD LEVELS OF PLASMA ANTIOXIDANT VITAMINS
AND PRUDENT DIET
The IHD-related cross-cultural findings in the Vitamin Substudy of
the WHO/MONICA Project! L 54 and the individual data from the
Edinburgh Case-Control Study on Previously Undiagnosed Angina
Pectoris65 suggest consistent thresholds of 'effective', ie presumably
'optimum' plasma levels which may be in the order of >28-30 |imol/l
lipid-standardized vitamin E, >40-50 |xmol/l vitamin C, >0.4-0.5
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jimol/1 (a- plus p-) carotene, >2.2-2.8 (imol/1 lipid-standardized vitamin
A. These levels agree also with individual data regarding both cancers37
and CVD12 in the Basle Prospective Study.
Although preventive potentials of an optimized antioxidant status
remain still conclusively to be proven, the presently still incomplete
observational data appear consistent enough for amendments of previ-
ous dietary guidelines. The latter have given general recommendations
to lower dietary fat (particularly of mammalian origin) with partial
replacement by monoene-rich vegetable oils and to increase the percent-
age of green-yellow vegetables/fruits. An updated prudent diet should
more specifically aim at a daily intake of antioxidant micronutrients
which can achieve the above mentioned 'safe' plasma levels: about 1
mg vitamin A (1 RDA), 60-250 mg vitamin C (1^4 times the present
RDA), at least 60-100 IU vitamin E (4-6 times the present RDA) and
about 6-15 mg P-carotene.10- 31, 69 Th e s e suggestions may, of course,
require adjustments for actual individual requirements, eg the desirable
plasma status of vitamin E should be defined not regarding concurrent
plasma lipids (as in common standardizations) but more specifically by
the vitamin E/PUFA ratio,14 similarly, the 'efficacy' of plasma vitamin
C or pVcarotene should also consider any extra source of exogenous
radicals, eg dietary oxidized lipids, smoking-derived and other envi-
ronmental radicals. Future studies will be needed on whether the WHO
goal of 'optimum human health* requires also 'effective' plasma levels
of oxygen-sensitive (presumably vitamin C-protected) micronutrients
such as folic acid or vitamin Bg17 as well as a minimal intake of pos-
sibly supportive plant antioxidants such as phenols/bioflavonoids64 or
carotenoids other than p-carotene.3> 20> 5 0
A different rank order of essential antioxidants regarding CVD and
cancer (and further variation by cancer site) and the likelihood of syn-
ergistic interactions between all antioxidants suggests that public health
measures should not improve the status of any single antioxidant but
rather aim at a general optimization of the overall antioxidant potential.7
The latter may be possible by common diets with suitable amounts and
variations of common fruit and vegetable items but in individuals or
populations at risk special recommendations may be needed, based on
the assay of the actual antioxidant status.
CONCEIVABLE MECHANISMS OF ACTION OF DIETARY
ANTIOXIDANTS IN DISEASE PREVENTION
Cancer
The in vivo mechanisms by which principal essential antioxidants
and singlet oxygen-quenching carotenoids could counteract mutagen-
esis and cancerogenesis are poorly understood. Radicals can certainly
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damage DNA70 but may independently act as tumour promoters.71
Deficiency of vitamin C causes oxidative DNA damage (eg 8-
hydroxydeoxyguanosine5) but impairs also immunoresponses.5- 16- 17
Improvement of the latter and possibly of overall tumour surveillance
has actually been reported for all essential antioxidants.16' 18 Exper-
imental vitamin A deficiency is well known to result in metaplasia
and facilitation of experimental tumours and, in the human, vitamin A
and/or P-carotene reverse the precancerous leukoplakia and reduce the
occurrence of pathological micronuclei even on continuous exposure
to mutagens from betel nuts and/or tobacco chewing.72 The conceiv-
able anti-cancer properties of P-carotene are presumably independent
from its potential function as provitamin A.17 The protective effects
of vitamin A (as related retinoids) and in part also of P-carotene may
be due to direct modulation of the expression of proto- and antionco-
genes although the intriguing underlying mechanisms are unclear.7^ All
essential antioxidants might also, at least in part, modulate secondary
messengers, eg by inhibition of adenylate cyclase.74 In some organs
special mechanisms may be of additional importance, eg protection of
the gastrointestinal tract against mutagens by vitamins C and E through
reduction of nitrosamine formation16- 75 or diminution of endogenous
faecal mutagens. 1(>> 17 In conclusion, the previously-studied principal
antioxidants may reduce tumour initiation and/or promotion by several
mechanisms. Cancer-preventive potentials remain further to be explored
for a series of hitherto widely neglected compounds from plants, eg
carotenoids other than P-carotene such as lycopenc2- 3- 2°> 50 as well as
the large fraction of mostly poorly absorbed but potent antioxidants and
metal chelators, such as common phenols and bioflavonoids.64 Special
attention should be devoted to some oxygen radical-sensitive B-vita-
mins such as folate and vitamin B$ which might require protection
by a fair vitamin C status5- 17- 67 and which are required to prevent
chromosomal damage and metaplasia.17
Cardiovascular disease
Although arteriosclerosis-like lesions due to chronic marginal defi-
ciency of vitamins C and E have been described in several animal
species10 the mechanisms of action have not been clarified. Free radical-
induced oxidation of low density lipoproteins (LDL) can clearly pro-
voke unregulated lipid accumulation in monocyte-derived macrophages
and thus presumably initiate atherogenesis by the formation of foam
cells and fatty streaks.76. 77 The quantitative importance of oxida-
tive LDL modifications in vivo, however, is still uncertain. Thus the
(copper-induced) oxidation rate of isolated LDL correlates only weakly
(r2=0.2) with coronary atherosclerosis in young survivors of myocar-
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dial infarction,78 and the considerable inter-individual variation of the
oxidative susceptibility of isolated LDL from healthy volunteers is nor-
mally not determined by its vitamin E content, although experimental
doubling of vitamin E in LDL can markedly improve the oxidation re-
sistance of isolated LDL, half of which is then explained by vitamin E.79
Since the first antioxidative defence line of plasma lipoproteins consists
actually of vitamin C4- 12> 79 it remains to be elucidated whether the
oxidation resistance of LDL in plasma depends in vivo on vitamin C
rather than on vitamin E but this may also be true for ubiquinol-10,81 an
endogenous antioxidant that can be increased by supplementation. Fur-
ther exploration is merited on the vitamin C-protected B-vitamins such
as folate, which normalizes moderate homocysteinemia82 and thus an-
other strong risk factor of CVD which is independent from classical risk
factors. Although protection of LDL has recently gained wide interest
as new potential antiatherosclerotic mechanism, essential antioxidants
have been reported to have many other beneficial effects that could also
counteract numerous crucial steps in atherogenesis10:
• in endothelium, eg inhibition of lipoxygenase(s) and thus of
oxidative LDL modification,76- 77 prevention of cellular tran-
sitions, reduction of monocyte adhesion
• in macrophages, eg modulation of their migration into the
subintimal space, reduction of the LDL-modifying 'respira-
tory burst' of radicals; improvement of the catabolism of mod-
ified LDL by resident macrophages resulting in diminished
foam cell formation, reduced production of crucial cytokines
such as interleukin-1 and thus regulation of cell-cell interac-
tions
• in smooth muscle cells, eg inhibition of proliferation and of
the signal transducing protein kinase
• in blood platelets, eg inhibition of adhesion
• improvements of immunoresponses.
CONCLUSIONS
The observational data reviewed above may corroborate the working
hypothesis that in the human a suboptimal status of essential antioxi-
dants (although with different rank orders for both CVD and cancer
as well as cancer sites) is involved in both cancerogenesis and athero-
genesis. Thus preventive potentials of essential antioxidants may be
expected which are, however, hardly restricted to single specific com-
pounds but rather due to various synergistic interactions of all anti-
oxidant micronutrients. Correspondingly, a variety of sequential and
interdependent mechanisms of action is conceivable for all essential
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antioxidants in both diseases and may even be needed since both can-
cerogenesis and atherogenesis have been accepted to be multifactorial
multi-stage processes. In consequence a steady optimization of the over-
all antioxidant potential (possibly still to be supplemented by other plant
components) rather than optimization of any single component seems
at present to offer the best preventive prospects. The above-described
observational data justify current and forthcoming intervention trials
which, if properly designed, may be hoped to verify the actual preven-
tive potentials of innocuous antioxidant micronutrients. All prophylactic
measures deserve high priority because of the great limitations in the
therapy of both major causes of death.
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